Subscribe to Newsletter

Content by Mark Hillen:

Subspecialties Cornea / Ocular Surface

Dropper Bother

| Mark Hillen

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) issues a safety alert for Cosopt preservative-free single-dose eye drops

Business & Profession Retina

20/200 Drivers

| Mark Hillen

Americans love their cars and in many places you’re virtually stranded if you don’t drive. So does vision loss stop elderly Americans from driving?

Subspecialties Basic & Translational Research

Keeping an Eye on Diabetes

| Mark Hillen

Transplanting pancreatic Islets of Langerhans into the ocular anterior chamber of the eye allows researchers to effectively monitor ?-cell function.

Business & Profession Cornea / Ocular Surface

Seeing What’s Behind the Camera

| Mark Hillen

The pupil of the eye is dark, and the cornea highly reflective – it acts as a mirror. Combine this with high resolution photography, and you get a whole new vista.

Subspecialties Professional Development

Not All Big Pharma Loves Ophtho

| Mark Hillen

While other pharmaceutical companies are buying into ophthalmology, Pfizer is heading for the hills

Business & Profession Other

Will Eye Bling Take Off?

| Mark Hillen

The media have been building up “eyeball jewelry” as a potential craze, but the evidence suggests otherwise

Business & Profession Basic & Translational Research

Cost: The Final Frontier

| Mark Hillen

Gene therapy for ocular disease will soon be available. Stem cell therapies too. They may be able to cure the currently untreatable, but at what price? And will anyone pay it?

Business & Profession Basic & Translational Research

Stem Cell Clinical Trials

| Irv Arons, Mark Hillen

Therapies based on stem cell treatments are considered to have tremendous potential in medicine.

Subspecialties Retina

Loss of Traction

| Mark Hillen

If you had VMT or MH and could avoid vitrectomy, you would. Might ocriplasmin let you?

Subspecialties Retina

Gazing into the MYRROR

| Mark Hillen

Bayer and Regeneron have presented the phase III trial data for aflibercept treatment of myopic choroidal neovascularization

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: